Innovent Biologics
Bin Zhou currently serves as the Executive Director of Corporate Strategy & Business Development at Innovent Biologics, a position held since April 2022. Prior experience includes the role of Chief Strategy Officer at LinkDoc Technology from May 2017 to April 2022 and an Associate position at McKinsey & Company from June 2014 to May 2017. Earlier in the career, Bin Zhou worked as a Senior Analytics Specialist at ElectrifAi from July 2010 to July 2012. Bin Zhou holds a Master of Philosophy (M.Phil.) in Economics from The Chinese University of Hong Kong, obtained between 2012 and 2014, and a Bachelor of Business Administration (B.B.A.) in Management Science from Fudan University, completed in 2010.
Innovent Biologics
2 followers
Innovent Biologics, Inc. is a China-based biopharmaceutical company. The Company's main products include PD-1 antibody; bevacizumab (Avastin) biosimilar, IBI-305; rituximab (MabThera/Rituxan) biosimilar, IBI-301; and adalimumab (Humira) biosimilar, IBI-303.